Ingredient Feature: Kinetin and Zeatin
02.24.2014, 10:53 CST | Posted In: Skin Care
Nature’s inherent processes have been a fascination for centuries for those in medicine – we study sharks for answers to cancer, plants for remedies to pain, we even use eggs to culture everything from vaccines to cosmetic facial injectables – the list goes on and on.
Plant-based growth factors provide another example of recent fascination. These cytokinins, as they are also called, have been synthesized and incorporated into topical skincare.
Two powerful types of cytokinins are Kinetin and Zeatin. Both Kinetin and Zeatin have been shown to be effective in improving the appearance of aging skin and are the key ingredients in Obagi’s product line designed for those with sensitive skin, the Gentle Rejuvenation System.
When researching the plant DNA-derived ingredient Kinetin, scientists discovered that this plant-based growth factor prevented plant leaves from drying out and withering. Soon, they realized the potential benefits Kinetin could have in skin care; they discovered that when synthesized and used topically in a 0.1% concentration, Kinetin gently, yet effectively can help keep skin looking smooth and radiant.1 In one study, 0.1% Kinetin cream used twice daily with an SPF 30 sunscreen, was shown to diminish the appearance of spots by an average of 60% in as early as 6 weeks.1 In another study using a 0.1% Kinetin lotion, patients saw a 26% increase in skin’s ability to retain moisture in 24 weeks.2
Zeatin is originally RNA-derived from immature corn kernels and occurs naturally in plants. It is now synthesized and added to topical skincare products. A study has shown that a 0.1% concentration of Zeatin used twice daily with an SPF 30 sunscreen in the morning, can improve skin appearance including roughness, fine lines and wrinkles, and reduce blotchiness in as little as 12 weeks.3
Last updated: 4/27/16
- Katz BE, Bruck MC. Efficacy and tolerability of kinetin 0.1% cream for improving the signs of photoaging in facial and neck skin. Cosmet Dermatol. 2006;19(12):736-741.
- McCullough JL, Weinstein GD. Clinical study of safety and efficacy of using topical kinetin 0.1% (Kinerase®) to treat photodamaged skin. Cosmet Dermatol. 2002;15(9):29-32.
- Cruz Jr. PD, Reece BT. A clinical study of topical zeatin (0.10%, 0.025%) for improving the appearance of photodamaged skin (RCTS study #1837). 12-week final analysis, September 2005. OMP, Inc. Data on file.
®/TMs are trademarks of Valeant Pharmaceuticals International, Inc. or its affiliates. All other product or brand names are trademarks of their respective owners. Distributed by Obagi Medical Products, a division of Valeant Pharmaceuticals North America LLC.
©2016 OMP, Inc. 4/16 GRS.0021.USA.16